

TRUSTED BY MORE THAN

7500+
PATIENTS

750+
ONCOLOGISTS

15+
PUBLICATIONS

10+
COUNTRIES



OncoStem RECAP OF 2024



MESSAGE FROM CEO

Dear Esteemed Patron,

On behalf of the OncoStem family, I extend warm wishes to all!

OncoStem continued its growth and R&D activities as planned in FY 2024. Our partnership with Zydus Life Sciences on CanAssist Breast (CAB) has gotten only stronger in the past year. We engaged via Zydus in valuable advisory meetings with many of you in the last 12 months and the inputs have been very insightful to push the envelope further. CanAssist Breast data continues to strengthen and was presented in key national and international conferences such as ABSI-CON in Lucknow, SABCS in San Antonio, ESMO in Barcelona, Breastanbul in Istanbul, and APBCS in Singapore. We completed a head-to-head prospective study comparing CanAssist Breast with Oncotype and Mammaprint with a group in Turkey, the results of which will be presented at ESMO-Breast in May in Munich, Germany. We have also completed validation of CAB in a second prospective randomized completed trial called IDEAL with our colleagues in Leiden, The Netherlands. The data shows that CAB can predict distant recurrences up to 15 years from diagnosis which will be published soon. The usefulness of CAB in day-to-day practice was published in 2 journals and a few posters in national and international conferences by our clinicians in India. It certainly makes us proud to see CAB data in conferences.

The reach of CanAssist Breast is increasing not only in India but in neighboring countries up to West Asia. Many clinicians and patients are thankful to have an alternate cost-effective prognostic test. Patients continue to give us testimonials which is very heartwarming and keeps us going in this journey.

I extend a heartfelt thanks to each of you for your unwavering belief in us and for contributing to making a meaningful difference in the lives of breast cancer patients with our Made in India prognostic test. Wishing you continued success and good health.

Regards
Manjiri

OncoStem Shines at Leading Oncology Conferences Across the World



GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE




CanAssist Breast (CAB) Test proudly presented its latest research at leading global conferences, including ESMO, SABCS, APBCS, ABSICON, and NATCON.


Our newest data highlighted the real-world application of the CAB test, sparking insightful discussions among clinicians and healthcare professionals. These findings further strengthened our commitment to advancing patient care through innovative and accessible prognostic solutions.




Dr. D. G. Vijay Presents on CAB and Proteomics-Based Risk Stratification in HR+/HER2-Negative Breast Cancer at St. Gallen Conference



CAB Latest Data Showcased at the APBCS 2025 Conference





Presented Real-World Data on CAB at The Prestigious SABCS 2024



At Breastanbul 2024, Dr. Manjiri and Dr. Tanay Shah Showcased CAB's Real-World Impact



Dr. Vashishth Maniar Shares New Real-World Insights on CAB at ESMO 2024




OncoStem at Indian Association of Surgical Oncology Annual Conference NATCON 2024



Dr. Somashekhar S.P. presented data on the usefulness of CAB in the real world.



OncoStem at ABSICON 2025: Highlights from Our Participation at the Event



OncoStem's CAB vs Excision Data Published



Cureus
Part of SPRINGER NATURE

Our recent study published in Cureus by Springer Nature compared the CanAssist Breast test on core needle biopsies and surgical specimens in hormone receptor-positive, HER2-negative early breast cancer.

Cureus
Part of SPRINGER NATURE

Open Access Original Article

Comparison of Risk Stratification by CanAssist Breast Test Performed on Core Needle Biopsies Versus Surgical Specimens in Hormone Receptor-Positive, Her2-Negative Early Breast Cancer

Review began 09/03/2024
Review ended 09/17/2024
Published 09/23/2024

© Copyright 2024

Savitha et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

DOI: 10.7759/cureus.70054

Badada Ananthamurthy Savitha¹, Payal Shrivastava¹, Rahul Bhagat¹, Naveen Krishnamoorthy¹, Deepti K. Shivashimpi¹, Manjiri M. Bakre²

1. Technical and Analytical Division, OncoStem Diagnostics Pvt. Ltd, Bengaluru, IND 2. Design and Development, OncoStem Diagnostics Pvt. Ltd, Bengaluru, IND

Corresponding author: Manjiri M. Bakre, manjiri@oncostemdiagnostics.com

Key Highlights and Milestones of the Year


Doubling Our Lab Capacity to Meet Growing Need with Greater Efficiency



Dr. Manjiri Bakre Participated in Tech Entrepreneurship Round Table at 'Celebrating Women Leaders in STEM' Hosted by Apollo Proton Cancer Centre



CME on CAB Conducted at Apollo Hospital, Ahmedabad; Dr. Savitha Shares Data on CanAssist Breast



Dr. Manjiri Bakre Took the Stage at the 2025 Technology & Innovation in Healthcare Summit by Happiest Health



Dr. Manjiri Joins Panel on Women in Tech at Global Entrepreneurship Conducted By Role of Returnee Entrepreneurs



OncoStem Diagnostics: Making Headlines!


Dr. Manjiri Bakre on Balancing Wellness and Leadership – Happiest Health, March 2025



Dr. Manjiri Bakre Featured on the Cover of Women's Entrepreneur Review – Women Leaders in Healthcare, October 2024



IT Madras Shastra Covers CanAssist Breast | 8th September 2024 Issue



CanAssist Breast Among 2024's Most Promising Brands | Times of India (Online), 20th April 2024



ZyduS Led Initiative to Advance Breast Cancer Awareness Last Year

Our Solution to Our Problem Campaign

As part of ZyduS's "Our Solution to Our Problem" campaign, we proudly showcased CanAssist Breast as a homegrown innovation for Indian patients. In line with our sustainability commitment, clinicians received bamboo water bottles, symbolizing local solutions like CanAssist Breast.

Dr. D.G. Vijay was among the clinicians who received this thoughtful token this under the doctors photo with the bottle



Dr. Chintamani Enlightens Students at GCRI Hospital, Ahmedabad; "Gurukul" Session in Delhi Draws Nationwide Participation

गुरुकुल इटरेटिव
Sangraha Clinical & Research Update
Banyan Seelap

Convenor: Prof. Chintamani

Hybrid Event
1st - 4th March 2024
Venue: Northern Railway Museum Auditorium, New Delhi

HIGHLIGHTS

- Live Administration of Clinical Examination in Surgery on India case
- Clinical Case Presentations & Discussion with eminent surgeons and distinguished faculty
- USCA/ASCA Examination for MSc/PhD/MS/FC exams based on recent pattern
- Ward Rounds
- Radiology & Pathology for Surgeons - Live Demonstration
- Attending Theory / Practicals by Expert Examiners

Registration OPEN !!
Click here to Register
<https://rhp.io/1/SCRUBS2024>

For any query, please write to us at gurukulgurugur@gmail.com

The Gujarat Cancer & Research Institute
(M.P. SHAH CANCER HOSPITAL) STATE CANCER INSTITUTE
AFFILIATED TO B. J. MEDICAL COLLEGE AHMEDABAD

Topic: Role of prognostication in the treatment of Early Breast Cancer
(ER+/PR+ HER 2Neu Negative Cases)



Speaker
Dr. (Prof.) Chintamani
Chairperson and Senior Consultant
Surgical Oncology
Sir Ganga Ram Hospital, Delhi

Date: 16th March, 2024
Time: 1:00 to 3:00 PM
Venue: GCRI Lecture Hall

Followed by High-Tech...



CanAssist Breast Information Leaflet Now Available in Nine Languages

English, Hindi, Marathi, Bengali, Odia, Kannada, Tamil, Telugu, and Punjabi

कैनअसिस्ट ब्रेस्ट® की शक्ति

भारत के 40 से अधिक करोड़ स्त्री, जिनमें 10% से अधिक स्त्री 40 वर्ष की आयु में कैनसर से ग्रस्त होती हैं। कैनअसिस्ट ब्रेस्ट® एक नया, सुरक्षित और प्रभावी उपचार है जो कैनसर को नियंत्रित करने में मदद करता है।

कैनअसिस्ट ब्रेस्ट® प्रभाव एवं विस्तार संबंधी विशिष्टताएं

- कैनसर: भारत के 40 से अधिक करोड़ स्त्री, जिनमें 10% से अधिक स्त्री 40 वर्ष की आयु में कैनसर से ग्रस्त होती हैं। कैनअसिस्ट ब्रेस्ट® एक नया, सुरक्षित और प्रभावी उपचार है जो कैनसर को नियंत्रित करने में मदद करता है।
- कैनसर: भारत के 40 से अधिक करोड़ स्त्री, जिनमें 10% से अधिक स्त्री 40 वर्ष की आयु में कैनसर से ग्रस्त होती हैं। कैनअसिस्ट ब्रेस्ट® एक नया, सुरक्षित और प्रभावी उपचार है जो कैनसर को नियंत्रित करने में मदद करता है।

अधिक जानकारी के लिए संपर्क करें:
info@canassistbreast.com
8888888888

स्वास्थ्य की हर राह आपकी चयन होगी अपनी राह पर!

ब्रेस्ट कैंसर

CanAssist Breast®
predicts risk of recurrence

जल्दी नहीं आपकी राह भी वहीं हो, जो औरों की है

ବ୍ୟାଞ୍ଜିତ୍ୱ ଶକ୍ତି

ଭାରତର 40 ଶହ କୋଟି ସ୍ତ୍ରୀ, ଯିଏ ମଧ୍ୟ 10% ଶହ କୋଟି ସ୍ତ୍ରୀ 40 ବର୍ଷରୁ ଉର୍ଦ୍ଧ୍ୱରେ କର୍କଶର ସହିତ ହୁଏ। କାନାସିସ୍ଟ ବ୍ରେସ୍ଟ® ଏକ ନିଉ, ସୁରକ୍ଷିତ ଏବଂ ପ୍ରଭାବୀ ଉପଚାର ଯାହା କର୍କଶକୁ ନିୟନ୍ତ୍ରଣ କରିବାରେ ସାହାଯ୍ୟ କରେ।

ବ୍ୟାଞ୍ଜିତ୍ୱ ଶକ୍ତି ପ୍ରଭାବ ଏବଂ ବିସ୍ତାର ସମ୍ବନ୍ଧୀୟ ବିଶେଷତା

- କର୍କଶ: ଭାରତର 40 ଶହ କୋଟି ସ୍ତ୍ରୀ, ଯିଏ ମଧ୍ୟ 10% ଶହ କୋଟି ସ୍ତ୍ରୀ 40 ବର୍ଷରୁ ଉର୍ଦ୍ଧ୍ୱରେ କର୍କଶର ସହିତ ହୁଏ। କାନାସିସ୍ଟ ବ୍ରେସ୍ଟ® ଏକ ନିଉ, ସୁରକ୍ଷିତ ଏବଂ ପ୍ରଭାବୀ ଉପଚାର ଯାହା କର୍କଶକୁ ନିୟନ୍ତ୍ରଣ କରିବାରେ ସାହାଯ୍ୟ କରେ।
- କର୍କଶ: ଭାରତର 40 ଶହ କୋଟି ସ୍ତ୍ରୀ, ଯିଏ ମଧ୍ୟ 10% ଶହ କୋଟି ସ୍ତ୍ରୀ 40 ବର୍ଷରୁ ଉର୍ଦ୍ଧ୍ୱରେ କର୍କଶର ସହିତ ହୁଏ। କାନାସିସ୍ଟ ବ୍ରେସ୍ଟ® ଏକ ନିଉ, ସୁରକ୍ଷିତ ଏବଂ ପ୍ରଭାବୀ ଉପଚାର ଯାହା କର୍କଶକୁ ନିୟନ୍ତ୍ରଣ କରିବାରେ ସାହାଯ୍ୟ କରେ।

ଅଧିକ ଜାଣିବା ପାଇଁ ସମ୍ପର୍କ କରନ୍ତୁ:
info@canassistbreast.com
8888888888

இந்தப் பிரச்சனை மீத, எங்கள் தீர்மானம்

CanAssist Breast®
predicts risk of recurrence

ଆପଣଙ୍କର ନାମ ଉପରେ ନିଜର ନାମ

The OncoStem team enjoyed a fun and engaging day of outdoor team-building

